GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclerion Therapeutics Inc (NAS:CYCN) » Definitions » Institutional Ownership

Cyclerion Therapeutics (Cyclerion Therapeutics) Institutional Ownership : 6.02% (As of May. 24, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cyclerion Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cyclerion Therapeutics's institutional ownership is 6.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cyclerion Therapeutics's Insider Ownership is 46.58%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cyclerion Therapeutics's Float Percentage Of Total Shares Outstanding is 65.73%.


Cyclerion Therapeutics Institutional Ownership Historical Data

The historical data trend for Cyclerion Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclerion Therapeutics Institutional Ownership Chart

Cyclerion Therapeutics Historical Data

The historical data trend for Cyclerion Therapeutics can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 13.81 13.72 13.76 9.94 7.05 6.07 6.11 5.55 6.02 6.02

Cyclerion Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cyclerion Therapeutics (Cyclerion Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Executives
Terrance Mcguire director C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Steven Hyman director C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Andreas Busch officer: Chief Scientific Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
George H Conrades director 500 TECHNOLOGY SQUARE, FIFTH FLOOR, CAMBRIDGE MA 02139
Stephanie Lovell director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Ole Isacson director CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kevin Churchwell director C/O CYCLERION THERAPEUTICS, CAMBRIDGE MA 02142
Michael Mendelsohn director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Peter M Hecht director, officer: Chief Executive Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Slate Path Capital Lp 10 percent owner 717 5TH AVENUE, 16TH FL., NEW YORK NY 10022
Errol B Desouza director 215 COLLEGE ROAD, PARAMUS NJ 07652
Anjeza Gjino officer: Chief Financial Officer C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Christopher I Wright officer: Chief Medical Officer C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Cheryl Gault officer: Chief Operating Officer CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Mark G Currie officer: President and CSO C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142

Cyclerion Therapeutics (Cyclerion Therapeutics) Headlines

From GuruFocus

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

By sperokesalga sperokesalga 05-11-2023